Document is current
Any future updates will be listed below
-
Authors
Overtchouk, Pavel
Piazza, Nicolo
Granada, Juan
Soliman, Osama
Prendergast, Bernard
Modine, Thomas https://orcid.org/0000-0003-4169-3766
- License Information
-
More Information
Article History
Received: 3 September 2019
Accepted: 18 December 2019
First Online: 7 January 2020
Ethics approval and consent to participate
: Review type of article. Not applicable.
: Review type of article. Not applicable.
: Dr. Thomas Modine is a consultant for Boston Scientific, Medtronic, Edwards, Cephea, Microport, GE, Abbott; he received a research support grant from Edwards. Dr. Nicolo Piazza declares to be consultant/proctor for HighLife, Medtronic and MicroPort, and is a consultant for Cephea. Dr. Juan Granada received Grant/Research Support by Abbott Vascular, Amaranth Medical, Angiometrix, AstraZeneca, Bioventrix, Boston Scientific, Caliber Therapeutics, Cardia, Cardiac Implants, Cagent, Cardiovascular Systems Inc., Cardiosolutions, Celladon, Cephea, Circulite/Heartware, ControlRad, CorindusVascular Robotics, CR Bard/Lutonix, DC Devices, Direct Flow Medical, Draper, Edwards LifeSciences, FulgurMedical, Guided Delivery Systems, Intact Vascular, Lutonix, Marvel Medical, Medtronic, Mercator, MedAlliance, MerilLife Sciences, Microvention, MicroInterventionalSystems, Mitralign, Neovasc, Nitiloop, Nitinotes, OrbusNeichMedical, REVA Medical, Siemens, Sonivie, Spectranetics, Svelte, Stentys, Surmodics, Thoratec, UniQure, Volcano, WL Gore, Zenvalve. Equity Position/Consulting in Cephea. Pavel Overtchouk declares no conflict of interest related to the presented work.
